A biomimetic nanovesicle for combined ultrasound-mediated regulation of neutrophil phenotype, its preparation method and application

By preparing biomimetic nanovesicles with lipid nanocores and hybrid biomembranes, loading them with sonosensitive agents and siRNA, and using ultrasound to activate ROS, the neutrophil phenotype is regulated, solving the problem of complex and ineffective neutrophil regulation in existing technologies, and achieving effective treatment against PD-1 resistant tumors.

CN121059835BActive Publication Date: 2026-11-10HENAN UNIVERSITY OF TECHNOLOGY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511113386.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-08-11
Publication Date
2026-11-10
Estimated Expiration
2045-08-11

AI Technical Summary

Technical Problem

In existing technologies, the methods for regulating the phenotype of neutrophils are complex and their anti-tumor effects need to be improved, especially in immune checkpoint blockade therapy, where immune resistance and low response rates lead to poor treatment outcomes.

Method used

Using biomimetic nanovesicles, a sonosensitive agent and functional siRNA are loaded through co-incubation of a lipid nanocore and a hybrid biomembrane. The sonosensitive agent is activated by ultrasound irradiation to generate ROS, which regulates the neutrophil phenotype, promotes the transformation of N2 neutrophils to N1 neutrophils, and combines with CAT to catalyze the decomposition of H2O2 in tumor tissue, thereby improving the tumor microenvironment.

Benefits of technology

It achieves effective regulation of neutrophil phenotype, enhances anti-tumor effects, especially the inhibition of PD-1 resistant tumors, induces long-term immune memory effects, and prevents tumor metastasis and recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121059835B_ABST
    Figure CN121059835B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically disclosing a biomimetic nanovesicle for combined ultrasound-mediated regulation of neutrophil phenotype, its preparation method, and its application. The biomimetic nanovesicles provided by this invention rupture under the influence of high concentrations of glutathione present in the tumor tissue microenvironment, releasing a sonosensitive agent and functional siRNA. Under US irradiation, the sonosensitive agent is activated, generating a large amount of ROS, which induces DNA breakage in tumor cells, generating a large amount of double-stranded DNA, activating APCs and promoting IFN-β release, thus causing N2-type neutrophils to transform into N1-type neutrophils. The released functional siRNA can prevent N1-type neutrophils from reverting back to N2-type neutrophils, thereby achieving regulation of the neutrophil phenotype. Under the catalysis of CAT-rich thylakoid membranes, the overexpressed H2O2 in tumor tissue is decomposed into oxygen, which can alleviate the hypoxic microenvironment of the tumor and improve the therapeutic effect of tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a biomimetic nanovesicle that combines ultrasound to regulate the phenotype of neutrophils and its preparation method, as well as the application of the biomimetic nanovesicle in the preparation of antitumor drugs. Background Technology

[0002] The application of immune checkpoint blockade (ICB) therapy has significantly changed cancer treatment. However, due to immune resistance and low response rates, many patients cannot benefit from immune checkpoint inhibitors (ICIs). Neutrophils, the most abundant white blood cells in the bloodstream, are the first line of defense against infection. Increasing evidence suggests that neutrophils play a multifaceted role in cancer development and progression, exhibiting heterogeneous phenotypes and functional plasticity. The N1 / N2 phenotype of neutrophils in cancer has been proposed, with N1 neutrophils exhibiting anti-tumor properties, while N2 neutrophils display tumor support and immunosuppressive functions. Therefore, modulating the phenotype of tumor-associated neutrophils (TANs)—that is, by inhibiting the pro-tumor neutrophil phenotype or repolarizing the pro-tumor phenotype to the anti-tumor phenotype—shows significant potential in cancer therapy.

[0003] Sonodynamic therapy (SDT) is a novel treatment for tumors that generates reactive oxygen species (ROS), offering non-invasive, tissue-penetrating, and spatiotemporally controllable benefits. Under ultrasound (US) irradiation, a sonosensitive agent induces the separation of electron-hole pairs. The released energy, electrons, and holes react with surrounding oxygen or water to produce highly oxidizing and cytotoxic ROS clusters, which damage biomolecules such as lipids, proteins, and DNA, thereby killing tumor cells. If N1 neutrophil therapy can be combined with sonodynamic therapy or other anticancer therapies (including chemotherapy, radiotherapy, molecular targeted therapy, photothermal therapy, photodynamic therapy, etc.), the synergistic effect between different mechanisms can enhance the anti-tumor effect, potentially offering promising clinical applications for the treatment of deep or large solid tumors. For example, Chinese patent CN113616790B (East China Normal University) discloses an engineered neutrophil sonosensitive drug delivery system, comprising neutrophils targeting tumor inflammation, and nanoparticles formed by loading an oxygen-carrying perfluorinated compound and a sonosensitive agent (selected from photoporphyrin, hematoporphyrin, hematoporphyrin monomethyl ether, etc.) into the neutrophils via an active targeting mechanism. This patent endows neutrophils with multi-level targeting capabilities, targeting both tumor inflammation sites and tumor cells, through nanoengineering, effectively promoting T-cell infiltration under ultrasound irradiation and improving immunotherapy efficacy. However, the preparation process of this nano-drug delivery system is complex, and its anti-tumor efficacy needs further improvement. Summary of the Invention

[0004] The main technical problem solved by this invention is to provide a biomimetic nanovesicle that combines ultrasound to regulate neutrophil phenotype. The biomimetic nanovesicles rupture under the influence of high concentrations of glutathione in the tumor tissue microenvironment, releasing a sonosensitizer and functional siRNA. Under US irradiation, the sonosensitizer is activated, generating a large amount of ROS, which causes tumor cell DNA to break down, generating a large amount of double-stranded DNA, activating APCs and promoting IFN-β release, thus causing N2-type neutrophils to transform into N1-type neutrophils. The released functional siRNA can prevent N1-type neutrophils from reverting back to N2-type neutrophils, thereby achieving regulation of neutrophil phenotype. Furthermore, under the catalysis of CAT-rich thylakoid membranes, the overexpressed H2O2 in tumor tissue is decomposed into oxygen, which can alleviate the hypoxic microenvironment of the tumor and improve the therapeutic effect of tumor treatment.

[0005] Secondly, this invention provides a method for preparing biomimetic nanovesicles that combine ultrasound regulation of neutrophil phenotype.

[0006] Furthermore, this invention provides an application of biomimetic nanovesicles that combine ultrasound regulation of neutrophil phenotype.

[0007] Finally, the present invention provides an anti-tumor drug.

[0008] To solve the above-mentioned technical problems, the present invention provides the following technical solutions:

[0009] A biomimetic nanovesicle for combined ultrasound-regulated neutrophil phenotype, wherein the biomimetic nanovesicle is obtained by co-incubation of a lipid nanocore and a hybrid biomembrane;

[0010] The raw materials for preparing the lipid nanocore include liposomes, sound-sensing agents, and functional siRNA;

[0011] The hybrid biomembrane was obtained by co-incubating macrophage membranes and thylakoid membranes.

[0012] The biomimetic nanovesicles provided by this invention have a shell formed by the fusion of a hybrid biological membrane and liposomes. A sonosensitizer is loaded in the lipid phase of the shell, while siRNA is loaded in the aqueous phase enclosed by the shell. The sonosensitizer works synergistically with siTGF-β to effectively inhibit the growth of tumors, including anti-PD-1 resistant tumors, induce long-term immune memory effects, and prevent tumor metastasis and recurrence.

[0013] In a preferred embodiment of the present invention, the mass ratio of the lipid nanocore to the hybrid biomembrane is (1-5):(0.2-1), preferably 5:1.

[0014] In a preferred embodiment of the present invention, the mass ratio of the liposome to the sound-sensitive agent is (1-10):(0.1-1), preferably 10:1.

[0015] In a preferred embodiment of the present invention, the mass ratio of the sonosensitive agent to siRNA is (12.5-18.75):(1-1.5), preferably 12.5:1.

[0016] In a preferred embodiment of the present invention, the protein mass ratio of the macrophage membrane to the thylakoid membrane is (1-3):(1-3), preferably 1:1.

[0017] As a preferred embodiment of the present invention, the raw materials for preparing the liposomes include, but are not limited to, one or more of phospholipids, cholesterol, DSPE-ss-PEGz (phospholipid-disulfide bond-polyethylene glycol, z value is 1000-5000).

[0018] Specifically, the raw materials for preparing the liposomes include phospholipids, cholesterol and DSPE-ss-PEGz, with a mass ratio of (2-10):1:(1-5), preferably 5:1:3.

[0019] Specifically, the phospholipid is soybean lecithin.

[0020] Specifically, the value of z in DSPE-ss-PEGz is 2000.

[0021] In a preferred embodiment of the present invention, the sound-sensing agent includes, but is not limited to, one or more of IR-780 iodide, hematoporphyrin monomethyl ether (HMME), and dihydroporphyrin e6 (Ce6). IR-780 iodide is preferred.

[0022] As a preferred embodiment of the present invention, the functional siRNA includes, but is not limited to, one or more of siRNAs that target TGF-β (abbreviated as siTGF-β).

[0023] Specifically, the nucleic acid sequence of siTGF-β is shown below:

[0024] sense strand: 5'-CGGACUACUAUGCUAAAGATT-3' (SEQ ID NO: 1);

[0025] antisense strand: 5'-UCUUUAGCAUAGUAGUCCGTT-3' (SEQ ID NO: 2).

[0026] Specifically, the functional siRNA is loaded onto a PAMAM molecule to form PAMAM-siRNA. The PAMAM molecule has an ethylenediamine core, -NH2 terminal groups, 100-200 terminal groups, and a theoretical molecular weight of 20,000-40,000 g / mol. The mass percentage of functional siRNA in the PAMAM-siTGF-β is 5%-10%.

[0027] As a preferred embodiment of the present invention, the source of the macrophage membrane includes, but is not limited to, one or more of RAW264.7 cells, autologous macrophages, etc.

[0028] As a preferred embodiment of the present invention, the source of the thylakoid membrane includes, but is not limited to, one or more of spinach thylakoids, lettuce thylakoids, and cabbage thylakoids.

[0029] In a preferred embodiment of the present invention, the lipid nanocore has a particle size of 100-130 nm.

[0030] In a preferred embodiment of the present invention, the biomimetic nanovesicles have a particle size of 170-200 nm.

[0031] A method for preparing biomimetic nanovesicles that combine ultrasound-mediated modulation of neutrophil phenotype includes the following steps:

[0032] The solution of liposome dissolving agent and the solution of sound-sensitive agent dissolving agent are mixed, and the solvent is removed to obtain a lipid film;

[0033] The lipid film was hydrated with a solution containing functional siRNA to obtain a lipid nanocore.

[0034] Macrophage membranes and thylakoid membranes were co-incubated to obtain hybrid biomembranes;

[0035] By co-incubating lipid nanocores with hybrid biomembranes, biomimetic nanovesicles with neutrophil phenotype regulated by combined ultrasound were obtained.

[0036] As a preferred embodiment of the present invention, the solution for dissolving liposomes is prepared by dissolving phospholipids, cholesterol, and DSPE-ss-PEGz (z value is 1000-5000) in chloroform in a certain proportion.

[0037] In a preferred embodiment of the present invention, the solvent removal is carried out by rotary evaporation at 45-60°C for 30-180 min.

[0038] In a preferred embodiment of the present invention, the hydration is carried out at room temperature, 20-25°C.

[0039] In a preferred embodiment of the present invention, the macrophage membrane is prepared by differential centrifugation, and the preparation steps include:

[0040] Centrifuge the lysed macrophages at 500-3000×g for 5-10 min;

[0041] Centrifuge the supernatant at 5000-10000×g for 5-10 min;

[0042] Centrifuge the supernatant at 50,000-100,000×g for 1-2 hours and collect the macrophage membranes.

[0043] In a preferred embodiment of the present invention, the thylakoid membrane is prepared by differential centrifugation, and the preparation steps include:

[0044] After homogenizing the spinach, filter it and centrifuge the filtrate at 6000-8000 rpm for 5-20 minutes.

[0045] After resuspending the sediment, centrifuge at 10,000-14,000 rpm for 20-40 min;

[0046] After resuspending the sediment, centrifuge at 14,000-20,000 rpm for 10-25 min to collect the thylakoid membrane.

[0047] In a preferred embodiment of the present invention, the co-incubation conditions for the macrophage membrane and thylakoid membrane are: treatment at 30-45°C for 5-20 min. Preferably, it is performed under ultrasound assistance, with the following conditions: 12% power, on for 5 s, off for 5 s, for 3-10 min.

[0048] In a preferred embodiment of the present invention, the conditions for co-incubating the lipid nanocore with the hybrid biomembrane are: treatment at 30-45°C for 5-20 minutes. Preferably, this is carried out under ultrasound assistance, with the same conditions as above.

[0049] An application of biomimetic nanovesicles that combine ultrasound-mediated modulation of neutrophil phenotype, including but not limited to one or more of the following aspects:

[0050] (1) Application in the preparation of antitumor drugs;

[0051] (2) Application in the preparation of formulations that silence TGF-β expression in the tumor intratumoral environment;

[0052] (3) Application in preparing a model for silencing TGF-β expression in the tumor intratumoral environment to screen antitumor drugs.

[0053] Specifically, the tumor is an anti-PD-1 resistant tumor. The biomimetic nanovesicles in the drug can effectively inhibit the growth of anti-PD-1 resistant tumors, induce long-term immune memory effects, and prevent tumor metastasis and recurrence.

[0054] Specifically, the formulation that silences TGF-β expression in the tumor intracellular environment can be a purely experimental formulation, rather than a therapeutic one, used to explore neutrophil reprogramming of the tumor intracellular environment and to screen for more drugs to treat tumors, but not to eliminate the cause or lesion.

[0055] An antitumor drug comprising biomimetic nanovesicles that combine ultrasound-mediated modulation of neutrophil phenotype.

[0056] As a preferred embodiment of the present invention, the antitumor drug further includes other antitumor pharmacological components, including but not limited to PD-1 / PD-L1 antibodies.

[0057] As a preferred embodiment of the present invention, the antitumor drug further includes pharmaceutically acceptable excipients, including but not limited to one or more of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent, buffer.

[0058] Specifically, the drug can be administered alone or formulated with excipients into a suitable dosage form for administration. The dosage form includes, but is not limited to, any one of tablets, powders, suspensions, granules, capsules, solutions, enemas, and emulsions.

[0059] In a preferred embodiment of the present invention, the antitumor drug is a single compound preparation or a combination of preparations of different active ingredients, which can be applied simultaneously, alternately, or sequentially.

[0060] The beneficial effects of this invention are:

[0061] This invention utilizes a phospholipid bilayer biomimetic nanoplatform to construct a specially structured biomimetic nanovesicle via membrane fusion technology. The macrophage membrane within the nanovesicle's outer shell prevents phagocytosis by macrophages, thus avoiding immune clearance and increasing blood circulation time. Simultaneously, it selectively targets tumor sites by leveraging the binding properties of overexpressed α4 or β1 integrins on the macrophage surface to vascular cell adhesion molecule-1 (VCAM-1) expressed on the tumor cell surface. Furthermore, under the catalysis of CAT-rich thylakoid membranes, the overexpressed H2O2 in tumor tissue is decomposed into oxygen, thereby improving the tumor immune microenvironment. The problem of hypoxia is addressed; simultaneously, the biomimetic nanovesicles rupture under the influence of high concentrations of glutathione in the tumor tissue microenvironment, releasing a somatosensitizer and siRNA targeting TGF-β. Under US irradiation, the somatosensitizer is activated to generate a large amount of ROS, which causes DNA breakage in tumor cells, generating a large amount of double-stranded DNA, activating APCs and promoting the release of IFN-β, causing N2 neutrophils to transform into N1 neutrophils. The released siTGF-β can further prevent N1 neutrophils from reverting back to N2 neutrophils, thereby achieving regulation of the neutrophil phenotype.

[0062] The present invention provides a method for preparing biomimetic nanovesicles. First, a lipid nanocore is synthesized using a thin-film dispersion method. Then, macrophage membranes and thylakoid membranes are prepared using differential centrifugation. These membranes are co-incubated to obtain a biomimetic hybrid membrane. Finally, the biomimetic hybrid membrane is co-incubated with the lipid nanocore to obtain a nanoscale drug delivery system. This preparation method is simple and easy to operate, suitable for industrial production. The biomimetic nanovesicles prepared in this way exhibit excellent antitumor activity. Through the synergistic effect of sonosensitive agents and siTGF-β, they effectively inhibit tumor growth (especially anti-PD-1 resistant tumors), induce long-term immune memory effects, and prevent tumor metastasis and recurrence, providing a novel treatment option for anti-PD-1 resistant tumors. Attached Figure Description

[0063] Figure 1 This is a schematic diagram illustrating the preparation process of the biomimetic nanovesicles that combine ultrasound regulation of neutrophil phenotype in this embodiment.

[0064] Figure 2 This is a particle size distribution diagram of different nano-formulations in the experimental examples.

[0065] Figure 3 The image shows the zeta potentials of different nano-formulations in the experimental examples.

[0066] Figure 4 The figure shows the particle size stability results of the biomimetic nanovesicles TRLIS in the experimental example after incubation in PBS for 7 days.

[0067] Figure 5 This is a transmission electron microscope (TEM) image of the biomimetic nanovesicles TRLIS in the experimental example.

[0068] Figure 6 The image shows the full wavelength scan of IR780, TK-R@Lip, TK-R@Lip-IR780, siTGF-β, and TK-R@Lip-siTGF-β in the experimental examples.

[0069] Figure 7 The figure shows the blood compatibility test results of the nanocarrier TK / R@Lip and the nanovesicles TK / R@Lip-IR780 / siTGF-β in the experimental example.

[0070] Figure 8 The image shows the cell viability of 4T1 cells after 24 hours of treatment with different drugs, determined by the CCK8 assay in the experimental example (*P<0.05, **P<0.01, ***P<0.001, ****P<0.001, data are expressed as mean ± standard deviation, n=3).

[0071] Figure 9 The image shows the ROS level results of 4T1 cells in the experimental case.

[0072] Figure 10 This is a statistical graph showing the tumor volume results of mice in each group in the experimental case.

[0073] Figure 11 This is a statistical graph showing the weight changes of mice in each group in the experimental case.

[0074] Figure 12 This is a statistical chart showing the tumor volume results of mice in each group using the combined drugs in the experimental case.

[0075] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings obtained in the experimental examples have been briefly described above. It should be understood that the above drawings only show some experimental examples of the present invention and should not be considered as any limitation on the scope of protection of the claims. For those skilled in the art, other related drawings can be obtained based on these drawings without any creative effort. Detailed Implementation

[0076] The technical solution of the present invention will be clearly and completely described below with reference to specific embodiments and experimental examples. However, those skilled in the art should understand that the embodiments are only used to illustrate the technical solution of the present invention and should not be regarded as limiting the scope of protection of the present invention. Based on the following embodiments, all other implementation schemes obtained by those skilled in the art without creative effort, such as implementation schemes obtained by modification, variation or simple substitution, should fall within the scope of protection of the present invention.

[0077] Unless otherwise specified, the experimental methods used in the following examples and experimental cases are conventional methods; the raw materials (including biological materials), reagents, culture media, instruments, etc. used are all commonly used in the field and commercially available to the public unless otherwise specified; the terms and abbreviations used have their conventional meanings in the field, such as PBS buffer being phosphate buffer.

[0078] Example

[0079] This embodiment provides a biomimetic nanovesicle for combined ultrasound-mediated regulation of neutrophil phenotype, obtained by co-incubation of a lipid nanocore and a hybrid biomembrane, with a lipid nanocore to hybrid biomembrane mass ratio of 5:1. The raw materials for preparing the lipid nanocore include liposomes, the sonosensitive agent IR-780 iodide, and siRNA targeting TGF-β (i.e., siTGF-β), with a liposome to IR-780 mass ratio of 10:1 and an IR-780 to siTGF-β mass ratio of 12.5:1. The raw materials for preparing the liposomes include phospholipids, cholesterol, and DSPE-ss-PEG. 2000 The mass ratio of the three components was 5:1:3. The hybrid biomembrane was obtained by co-incubating macrophage membranes and thylakoid membranes, with a mass ratio of macrophage membrane to thylakoid membrane of 1:1. siTGF-β was loaded onto PAMAM molecules to form PAMAM-siTGF-β, with a siTGF-β mass percentage of 8.3%. The PAMAM molecule had an ethylenediamine core, -NH2 terminal groups, 128 terminal groups, and a theoretical molecular weight of 28826 g / mol (purchased from Weihai Chenyuan Molecular New Materials Co., Ltd., brand name: CYD-150A). The nucleic acid sequence of siTGF-β is shown below:

[0080] sense strand: 5'-CGGACUACUAUGCUAAAGATT-3';

[0081] antisense strand: 5'-UCUUUAGCAUAGUAGUCCGTT-3'.

[0082] The biomimetic nanovesicles for combined ultrasound-regulated neutrophil phenotype provided in this embodiment have shells formed by the fusion of hybrid biological membranes and liposomes. IR-780 is loaded in the lipid phase of the shell, and siTGF-β is loaded in the aqueous phase encapsulated by the shell. The preparation method (see schematic diagram) is as follows. Figure 1 This includes the following steps:

[0083] (1) Preparation of biomimetic hybrid biomembrane (TK / R):

[0084] (1.1) Preparation of thylakoid membrane (TK):

[0085] (1.1.1) First, take 25g of fresh spinach leaves, wash them with distilled water, and store them in the dark at 4℃ for 12h.

[0086] (1.1.2) Subsequently, the spinach leaves were cut into small pieces and placed in 75 mL of HEPES buffer (10 mM, pH 7.6) containing 5 mM MgCl2, 50 mM NaCl and 0.3 M sucrose. The mixture was then placed at 4 °C in the dark for 45 min.

[0087] (1.1.3) After that, the spinach homogenate was ground in an ice mortar and then filtered through 10 layers of cotton gauze to remove leaf fragments. The filtrate was centrifuged at 8000 rpm for 10 min to collect the intact chloroplast deposits.

[0088] (1.1.4) The sediment was resuspended in HEPES buffer (10 mM, pH 8.0), allowed to stand at 4 °C for 4 h, and then centrifuged at 12000 rpm for 30 min. The matrix extract was removed from the supernatant, and the thylakoid-rich particulate sediment was collected.

[0089] (1.1.5) Take the sediment, wash it twice with 10mM HEPES buffer, resuspend it with distilled water, centrifuge at 16000rpm for 15min to obtain TK with dark green particles, and store it in a -80℃ freezer for later use.

[0090] (1.2) Preparation of macrophage membrane (RAW):

[0091] (1.2.1) Collect the lysate containing macrophages in a 1.5 mL centrifuge tube and lyse it on ice for 15 min.

[0092] (1.2.2) The homogenate was obtained by freezing and thawing five times in liquid nitrogen and a water bath at 37°C.

[0093] (1.2.3) Take the homogenate and centrifuge it at 500×g for 10min.

[0094] (1.2.4) Take the supernatant and centrifuge at 10000×g for 10min.

[0095] (1..2.5) Take the supernatant and centrifuge at 70000×g for 1h, resuspend in an appropriate volume of PBS, and store at -80℃.

[0096] (1.3) Preparation of hybrid membranes:

[0097] The extracted TK and RAW membrane proteins were quantitatively analyzed using the BCA protein kit. Subsequently, the TK and RAW membranes were prepared into a 1:1 protein concentration solution and incubated with shaking at 37°C for 20 min. Then, ultrasonic-assisted treatment was performed (conditions: 12% power, on 5 s, off 5 s, 5 min, using Ningbo Xinzhi Bio-ultrasonic Cell Disruptor JY92-IIDN) to obtain a hybrid TK / R membrane solution.

[0098] (2) Preparation of the nanomedicine TRLIS:

[0099] (2.1) Preparation of Lip-IR780 / siTGF-β:

[0100] (2.1.1) Dissolve 1 mg of IR780 in 2 mL of methanol to obtain solution A; dissolve soybean lecithin, cholesterol, and DSPE-ss-PEG2000 in chloroform at a mass ratio of 5:1:3 to obtain 10 mg of lipid solution B. Then mix solution A and lipid solution B in a round-bottom flask, remove the solvent by rotary evaporation, and obtain a lipid film (abbreviated as Lip-IR780) at the bottom of the flask.

[0101] (2.1.2) Then, 1 mL of PBS solution containing PAMAM-siTGF-β (siTGF-β is 80 μg / mL) was added to the lipid film and hydrated at room temperature to obtain the lipid nanocore Lip-IR780 / siTGF-β.

[0102] The preparation method of PAMAM-siTGF-β is as follows: 1.1 mg of PAMAM is dissolved in 0.1 mL of PBS, and 0.1 mg of siTGF-β is dissolved in 0.1 mL of DEPC water. After mixing the two, the mixture is shaken and incubated at 37 °C for 30 min to obtain a PBS solution containing PAMAM-siTGF-β.

[0103] (2.2) Preparation of TK / R@Lip-IR780 / siTGF-β:

[0104] The lipid nanocore Lip-IR780 / siTGF-β was added to the hybrid TK / R membrane solution prepared in (1.3), and co-incubated at 37℃ for 10 min. After ultrasonic-assisted treatment (conditions: 12% power, on 5s, off 5s, 5min), uniform biomimetic nanovesicles TK / R@Lip-IR780 / siTGF-β were obtained.

[0105] This embodiment also provides an application of biomimetic nanovesicles that combine ultrasound modulation of neutrophil phenotype, including but not limited to one or more of the following aspects:

[0106] (1) Its application in the preparation of antitumor drugs to inhibit tumor metastasis and recurrence;

[0107] (2) Application in the preparation of formulations that silence TGF-β expression in the tumor intratumoral environment;

[0108] (3) Application in preparing a model for silencing TGF-β expression in the tumor intratumoral environment to screen antitumor drugs.

[0109] This embodiment also provides an antitumor drug, comprising a pharmaceutically effective amount of biomimetic nanovesicles and a PD-1 antibody, as well as an appropriate amount of pharmaceutically acceptable excipients.

[0110] In other embodiments of the present invention, the amount of each component in the biomimetic nanovesicles can be arbitrarily selected within a given range without significantly affecting the physicochemical properties, biological functions, and therapeutic effects of the nanovesicles.

[0111] In other embodiments of the present invention, the raw materials, preparation parameters, and conditions for the preparation of biomimetic nanovesicles can be arbitrarily selected within a given range, without significantly affecting the physicochemical properties, biological functions, and therapeutic effects of the nanovesicles.

[0112] Experimental Example

[0113] 1. Particle size and zeta potential analysis of nanomedicine TK / R@Lip-IR780 / siTGF-β

[0114] A small amount of liposomes Lip (blank liposomes without IR780 and siTGF-β loading), Lip-IR780, Lip-IR780 / siTGF-β, and TK / R@Lip-IR780 / siTGF-β prepared in each step of the examples were taken, prepared according to the examples. The samples were diluted with PBS, and the particle size and polydispersity index (PDI) of the samples were determined using a particle size analyzer. The particle size was measured daily for 7 days a week to assess the stability of the nanomaterials. Then, the potentials of Lip, Lip-IR780, Lip-IR780 / siTGF-β, and TK / R@Lip-IR780 / siTGF-β were measured using the same method with a potentiometer. The obtained data were processed and analyzed using GraphPadPrism 8.

[0115] The particle size analysis results for each sample group are as follows: Figure 2As shown, by optimizing the addition amounts of soybean phospholipids, cholesterol, and DSPE-ss-PEG2k, liposomes with a particle size of (112.9±2.9) nm were synthesized. With further modification, the hydrated particle size gradually increased, and the hydrated particle size of the nanomedicine TRLIS was (147.2±0.8) nm.

[0116] The zeta potential detection results for each sample group are as follows: Figure 3 As shown, the potential of liposome Lip was (-27.4±0.8) mV. With gradual loading of IR780 and siTGF-β, the potential of Lip-IR780 / siTGF-β gradually increased to (-9.7±0.9) mV, with positive and negative values ​​representing the charge carried by the particles. The hybrid biomembrane is negatively charged; therefore, after co-incubation of the lipid nanocore and the hybrid membrane, the potential of the nanocomposite decreased to (-13.9±1.2) mV, consistent with the expected results.

[0117] The particle size analysis results of the biomimetic nanovesicles TRLIS after 7 days of storage are as follows: Figure 4 As shown, the hydrodynamic diameter of the nanovesicles TRLIS remained essentially unchanged after 7 days in PBS, indicating that the nanovesicles have stable and uniform particle size and good biological stability.

[0118] 2. Morphology testing of the nanoparticle-based drug TK / R@Lip-IR780 / siTGF-β

[0119] A small amount of TK / R@Lip-IR780 / siTGF-β was diluted to 0.2 mg / mL with PBS. 20 μL of the suspension was repeatedly dropped onto a carbon-coated copper grid. After standing for 10 min, excess nanomaterials were removed with filter paper. The copper grid was then stained with 20 μL of 3% uranium acetate in the dark for 10 min. After standing, excess staining reagent was removed with filter paper. The morphology of the nanomaterials was observed and photographed using a transmission electron microscope. The results are as follows: Figure 5 As shown.

[0120] 3. Ultraviolet full-wavelength scanning of nanomedicine TK / R@Lip-IR780 / siTGF-β

[0121] Successful loading of IR780 and siTGF-β onto nanocarriers was determined using a UV spectrophotometer. IR780, TK-R@Lip, TK-R@Lip-IR780, siTGF-β, and TK-R@Lip-siTGF-β were diluted and scanned in the wavelength range of 200–800 nm using a UV spectrophotometer.

[0122] The results are as follows Figure 6As shown, the nanomedicine TK-R@Lip-IR780 / siTGF-β exhibits significant ultraviolet absorption at the maximum absorption wavelength of IR780 (780 nm) and siTGF-β (260 nm), indicating the successful construction of nanovesicles.

[0123] 4. Blood compatibility study of nanomedicine TK / R@Lip-IR780 / siTGF-β

[0124] First, a 2% fresh red blood cell suspension was prepared and co-incubated with different concentrations of nanocarriers (TK / R@Lip, differing from the example only in that the lipid nanocores are not loaded with IR780 and siTGF-β, and the preparation method is basically the same as the example) and nanovesicles TK / R@Lip-IR780 / siTGF-β at 37°C for 1 hour. The suspension was then centrifuged, and the absorbance of the supernatant at 540 nm was measured. PBS buffer was used as a negative control, and Triton X-100 (1%) as a positive control. The hemolysis index was calculated using the following formula:

[0125]

[0126] The results are as follows Figure 7 As shown, the concentration of nanoparticles and the lysis of erythrocytes generally exhibit a positive linear correlation. In the negative control tube, intact erythrocytes without hemolytic activity were observed in the supernatant, and a firm, dark red precipitate was present at the bottom of the tube. According to ASTM E 2524-2008, the nanocarrier TK / R@Lip and the nanovesicles TK / R@Lip-IR780 / siTGF-β are in a relatively safe state in blood circulation, with hemolysis indices within the normal range, exhibiting low hemolytic activity in blood. This lays the foundation for the successful conduct of in vivo experiments.

[0127] 5. Antitumor research on the nanomedicine TK / R@Lip-IR780 / siTGF-β at the cellular level

[0128] (1) Assess cytotoxicity using a typical CCK-8 reduction assay

[0129] First, 4T1 cells were seeded into 96-well plates. After cell adhesion, drugs were administered, with different drug concentrations designated as experimental groups and complete culture medium as the control group. 4T1 cells were incubated for 12 hours with IR780, siTGF-β, TK / R@Lip-IR780 (different from the example in that it only loads IR780 without siTGF-β, the preparation method is basically the same as the example), TK / R@Lip-siTGF-β (different from the example in that it only loads siTGF-β without IR780, the preparation method is basically the same as the example), and TK / R@Lip-IR780 / siTGF-β (TRLIS) under different drug concentrations. Afterward, the cells were irradiated with or without ultrasound (1.0 MHz, 50% duty cycle, 1.5 W / cm²). 2 After incubation for 1 min, the cells were incubated for another 12 h, then 100 μL of LCK-8 solution (0.5 mg / mL) was added, and the cells were incubated in the dark at 37°C for 2 h with 5% carbon dioxide. The absorbance of each well was then measured at 450 nm using a microplate reader, and the cell viability of each experimental group was calculated to evaluate the toxicity of the constructed nano-formulation to normal cells and tumor cells. The experiment was repeated 3 times (the dosage of the corresponding drugs in each treatment group was kept consistent, i.e., the dosage of IR780 in the TRLIS group was the same as that in the TK / R@Lip-IR780 group and the IR780 group, and the dosage of siTGF-β in the TRLIS group was the same as that in the TK / R@Lip-siTGF-β group and the siTGF-β group, and the subsequent experiments were the same, so they will not be repeated).

[0130] The experimental results of the 4T1 cell group are as follows: Figure 8 As shown, the survival rates of cells treated with TK / R@Lip-IR780, TK / R@Lip-siTGF-β, and TRLIS nanoparticles were lower than those treated with naked IR780 and naked siTGF-β, indicating that nanoparticles can selectively accumulate in tumor cells, enhancing their anti-tumor effects. The number of cells in all ultrasound-treated groups was lower than in the untreated groups, suggesting that ultrasound combined with other treatments is more beneficial to the effect of IR780, inducing immunogenic cell death in tumor cells. Furthermore, the survival rate of cells treated with TRLIS was even lower than that of TK / R@Lip-IR780 and TK / R@Lip-siTGF-β, because IR780 and siTGF-β simultaneously amplified the anti-tumor effects of the nanomedicines.

[0131] (2) Intracellular ROS levels were detected by staining with the fluorescent dye 2,7-dichlorodihydrofluorescein (DCFH-DA).

[0132] 4T1 cells (1×10) 5Cells were seeded at 5 μg / well in 6-well plates and co-incubated with PBS, PBS(+), free IR780+siTGF-β(+), R@Lip-IR780 / siTGF-β(+), TK / R@Lip-IR780 / siTGF-β, and TK / R@Lip-IR780 / siTGF-β(+), respectively. After 6 h, the groups requiring ultrasound treatment were irradiated with ultrasound. After 4 h, the culture medium was discarded, and the cells were washed with cold PBS. The cells were then incubated with a 5 μL LCFH-DA (10 mM) probe for 40 min, and the fluorescence intensity of the cells was observed under a fluorescence microscope.

[0133] The results are as follows Figure 9 As shown, 4T1 cells treated with ultrasound in the free IR780+siTGF-β(+) group exhibited a slight increase in green fluorescence, which is attributed to the generation of ROS by IR780 sonodynamic therapy. 4T1 cells treated with R@Lip-IR780 / siTGF-β(+) and TK / R@Lip-IR780 / siTGF-β showed stronger green fluorescence than the free IR780+siTGF-β(+) group, due to the efficient drug delivery capability of the nanocarriers. The significantly enhanced green fluorescence in TK / R@Lip-IR780 / siTGF-β(+) treated cells indicates that catalase on the TK membrane effectively increases the oxygen content in the tumor microenvironment and promotes ROS generation under ultrasound irradiation.

[0134] 6. Antitumor Study of Nanomedicine TK / R@Lip-IR780 / siTGF-β in Animals

[0135] (1) 1×10 6 4T1 cells were injected subcutaneously into the right hind limb of mice to construct a 4T1 subcutaneous tumor model.

[0136] (2) Seven days later, the mice were randomly divided into eight groups, with an average tumor volume of 100 mm in each group. 3 (n=5). Subsequently, mice were injected via tail vein with the following groups: G1: PBS group, G2: PBS(+) group, G3: siTGF-β group, G4: free IR780(+) group, G5: R@Lip-IR780 / siTGF-β(+) group, G6: TK@Lip-IR780 / siTGF-β(+) group, G7: TK / R@Lip-IR780 / siTGF-β, and G8: TK / R@Lip-IR780 / siTGF-β(+) (IR780 was 7 mg / kg, and siTGF-β was 0.6 mg / kg). Drug treatment and ultrasound irradiation were performed every two days. The in vivo therapeutic effect of the drug was observed by monitoring tumor volume and body weight in the mice.

[0137] (3) After treatment, the mice were euthanized by cervical dislocation. The tumor tissue was then dissected, and the tumor volume was calculated as length × width. 2 / 2(mm 3 ), where the length is the longest dimension and the width is the vertical dimension.

[0138] Tumor volume results for each group of mice are as follows: Figure 10 As shown, compared to the free siTGF-β group and the IR780(+) group, R@Lip-IR780 / siTGF-β(+) exhibited enhanced antitumor efficacy. This phenomenon is attributed to the fact that the overexpressed α4 or β1 integrins on the RAW membrane surface can bind to vascular cell adhesion molecule-1 expressed on the tumor cell surface, thereby achieving effective tumor targeting. Compared to the free siTGF-β group and the IR780(+) group, the TK@Lip-IR780 / siTGF-β(+) treatment group exhibited enhanced antitumor efficacy. This phenomenon is attributed to the fact that CAT in the TK membrane enhances the ROS-induced tumor cell killing effect. In conclusion, the hybrid biomimetic design of RAW and TK membranes can significantly improve the antitumor effect of TK / R@Lip-IR780 / siTGF-β(+).

[0139] The changes in body weight of mice in each group are as follows: Figure 11 As shown, this indicates that the biomimetic nanovesicles have good biosafety.

[0140] 7. Study on the enhanced antitumor effect of nanomedicine TK / R@Lip-IR780 / siTGF-β combined with PD-1 antibody

[0141] (1) 1×10 6 4T1 cells were injected subcutaneously into the right hind limb of mice to construct a 4T1 subcutaneous tumor model.

[0142] (2) Seven days later, the mice were randomly divided into four groups, with an average tumor volume of 100 mm in each group. 3 (n=5). Subsequently, mice were intraperitoneally injected with G1: PBS group, G2: anti-PD-1 group, G3: TK / R@Lip-IR780 / siTGF-β(+) group, and G4: anti-PD-1+TK / R@Lip-IR780 / siTGF-β(+) group (IR780 7 mg / kg, siTGF-β 0.6 mg / kg; PD-1 antibody 5 mg / kg). Drug treatment and ultrasound irradiation were performed every two days. The in vivo therapeutic effect of the drugs was observed by monitoring tumor volume in the mice.

[0143] (3) After treatment, the mice were euthanized by cervical dislocation. The tumor tissue was then dissected, and the tumor volume was calculated as length × width. 2 / 2(mm 3), where the length is the longest dimension and the width is the vertical dimension.

[0144] The changes in body weight of mice in each group are as follows: Figure 12 As shown, groups G2 and G3 exhibited moderate inhibitory effects on tumors, while group G4 showed significant inhibitory effects, with tumor volume being 56% of the control group. These results indicate that the nanomedicine prepared in this invention, combined with PD-1 antibody therapy, can effectively inhibit tumor growth.

[0145] Although the technical solution of the present invention has been described in detail above with general descriptions, specific embodiments, and experimental examples, it should be noted that the embodiments and experimental examples are only used to illustrate the technical solution and technical effects of the present invention, and should not be regarded as any limitation on the scope of protection of the present invention. Simple modifications, alterations, or improvements made based on the technical concept of the present invention are all within the scope of protection claimed by the present invention.

Claims

1. A biomimetic nanovesicle for combined ultrasound-mediated regulation of neutrophil phenotype, characterized in that: The biomimetic nanovesicles were obtained by co-incubation of a lipid nanocore and a hybrid biological membrane. The raw materials for preparing the lipid nanocore include liposomes, sound-sensing agents, and functional siRNA; The hybrid biomembrane was obtained by co-incubation of macrophage membrane and thylakoid membrane; The raw materials for preparing the liposomes include phospholipids, cholesterol, and DSPE-ss-PEGz; The functional siRNA is a siRNA that targets TGF-β, and the nucleic acid sequence of the TGF-β-targeting siRNA is shown below: sense strand: 5'-CGGACUACUAUGCUAAAGATT-3'; antisense strand: 5'-UCUUUAGCAUAGUAGUCCGTT-3'.

2. The biomimetic nanovesicles according to claim 1, characterized in that: The mass ratio of the lipid nanocore to the hybrid biomembrane is (1-5):(0.2-1). And / or, the mass ratio of the liposome to the sonosensitive agent is (1-10):(0.1-1); And / or, the mass ratio of the sonosensitive agent to siRNA is (12.5-18.75):(1-1.5); And / or, the protein mass ratio of the macrophage membrane to the thylakoid membrane is (1-3):(1-3); And / or, the lipid nanocore has a particle size of 100-130 nm; And / or, the biomimetic nanovesicles have a particle size of 170-200 nm.

3. The biomimetic nanovesicles according to claim 1, characterized in that: In the DSPE-ss-PEGz, the value of z is 1000-5000; And / or, the sound-sensitive agent is selected from one or more of IR-780 iodide, hematoporphyrin monomethyl ether, and dihydroporphyrin e6; And / or, the functional siRNA is loaded onto the PAMAM molecule to form PAMAM-siRNA; the mass percentage of functional siRNA in the PAMAM-siRNA is 5%-10%; And / or, the macrophage membrane is derived from one or more of RAW264.7 cells and autologous macrophages; And / or, the source of the thylakoid membrane is selected from one or more of spinach thylakoids, lettuce thylakoids, and cabbage thylakoids.

4. The biomimetic nanovesicles according to claim 3, characterized in that: The raw materials for preparing the liposomes include phospholipids, cholesterol and DSPE-ss-PEGz, with a mass ratio of (2-10):1:(1-5).

5. A method for preparing biomimetic nanovesicles with combined ultrasound-regulated neutrophil phenotype as described in any one of claims 1-4, characterized in that: Includes the following steps: The solution of liposome dissolving agent and the solution of sound-sensitive agent dissolving agent are mixed, and the solvent is removed to obtain a lipid film; The lipid film was hydrated with a solution containing functional siRNA to obtain a lipid nanocore. Macrophage membranes and thylakoid membranes were co-incubated to obtain hybrid biomembranes; By co-incubating lipid nanocores with hybrid biomembranes, biomimetic nanovesicles with neutrophil phenotype regulated by combined ultrasound were obtained.

6. The preparation method according to claim 5, characterized in that: The solution for dissolving liposomes is prepared by dissolving phospholipids, cholesterol, and DSPE-ss-PEGz in chloroform in a certain proportion. And / or, the solvent removal is performed by rotary evaporation at 45-60°C for 30-180 min; And / or, the hydration is carried out at room temperature, at a temperature of 20-25°C; And / or, the macrophage membrane is prepared by differential centrifugation, and the preparation steps include: Centrifuge the lysed macrophages at 500-3000×g for 5-10 min; Centrifuge the supernatant at 5000-10000×g for 5-10 min; Centrifuge the supernatant at 50,000-100,000×g for 1-2 h and collect the macrophage membranes; And / or, the thylakoid membrane is prepared by differential centrifugation, and the preparation steps include: After homogenizing the spinach, filter it and centrifuge the filtrate at 6000-8000 rpm for 5-20 min. After resuspending the sediment, centrifuge at 10,000-14,000 rpm for 20-40 min; After resuspending the sediment, centrifuge at 14,000-20,000 rpm for 10-25 min to collect the thylakoid membrane; And / or, the conditions for co-incubating the macrophage membrane and thylakoid membrane are: treatment at 30-45℃ for 5-20 min; And / or, the conditions for co-incubating the lipid nanocore with the hybrid biomembrane are: treatment at 30-45℃ for 5-20 min.

7. The application of a biomimetic nanovesicle with combined ultrasound-regulated neutrophil phenotype as described in any one of claims 1-4 in the preparation of an anti-breast cancer drug.

8. An antitumor drug, characterized in that: The antitumor drug includes the biomimetic nanovesicles described in claim 1, which combine ultrasound-mediated regulation of neutrophil phenotype.

9. The antitumor drug according to claim 8, characterized in that: The antitumor drug also includes other antitumor active ingredients, which are selected from PD-1 / PD-L1 antibodies; And / or, the antitumor drug further includes pharmaceutically acceptable excipients selected from one or more of fillers, binders, wetting agents, disintegrants, emulsifiers, solubilizers, osmotic pressure regulators, coating materials, colorants, antioxidants, antibacterial agents, and buffers; And / or, the drug is a single compound preparation, or a combination of preparations of different pharmacodynamic ingredients individually.

Citation Information

Patent Citations

  • An engineered neutrophil acoustic sensitizer drug delivery system and its application

    CN113616790B

  • Bionic epigenetic nano regulator based on ultrasonic response as well as preparation method and application of bionic epigenetic nano regulator

    CN117503927A